These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31525197)

  • 1. Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans.
    George PJ; Hess JA; Jain S; Patton JB; Zhan T; Tricoche N; Zhan B; Bottazzi ME; Hotez PJ; Abraham D; Lustigman S
    PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007730. PubMed ID: 31525197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice.
    Hess JA; Zhan B; Torigian AR; Patton JB; Petrovsky N; Zhan T; Bottazzi ME; Hotez PJ; Klei TR; Lustigman S; Abraham D
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004797. PubMed ID: 27387453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
    Cho-Ngwa F; Liu J; Lustigman S
    PLoS Negl Trop Dis; 2010 Aug; 4(8):e800. PubMed ID: 20808763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity.
    MacDonald AJ; Tawe W; Leon O; Cao L; Liu J; Oksov Y; Abraham D; Lustigman S
    Parasite Immunol; 2004 Jan; 26(1):53-62. PubMed ID: 15198646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+-dependent immunity to Onchocerca volvulus third-stage larvae in humans and the mouse vaccination model: common ground and distinctions.
    Lustigman S; MacDonald AJ; Abraham D
    Int J Parasitol; 2003 Sep; 33(11):1161-71. PubMed ID: 13678632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of an OV-16 IgG4 Enzyme-Linked Immunosorbent Assay in Humans and Its Application to Determine the Dynamics of Antibody Responses in a Non-Human Primate Model of
    Cama VA; McDonald C; Arcury-Quandt A; Eberhard M; Jenks MH; Smith J; Feleke SM; Abanyie F; Thomson L; Wiegand RE; Cantey PT
    Am J Trop Med Hyg; 2018 Oct; 99(4):1041-1048. PubMed ID: 30062989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model.
    Hess JA; Zhan B; Bonne-Année S; Deckman JM; Bottazzi ME; Hotez PJ; Klei TR; Lustigman S; Abraham D
    Int J Parasitol; 2014 Aug; 44(9):637-46. PubMed ID: 24907553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a recombinant antigen vaccine against infection with the filarial worm Onchocerca volvulus.
    Abraham D; Leon O; Leon S; Lustigman S
    Infect Immun; 2001 Jan; 69(1):262-70. PubMed ID: 11119514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental onchocerciasis in chimpanzees: cellular responses and antigen recognition after immunization and challenge with Onchocerca volvulus infective third-stage larvae.
    Lüder CG; Soboslay PT; Prince AM; Greene BM; Lucius R; Schulz-Key H
    Parasitology; 1993 Jul; 107 ( Pt 1)():87-97. PubMed ID: 8356001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA immunization with Onchocerca volvulus genes, Ov-tmy-1 and OvB20: serological and parasitological outcomes following intramuscular or GeneGun delivery in a mouse model of onchocerciasis.
    Harrison RA; Bianco AE
    Parasite Immunol; 2000 May; 22(5):249-57. PubMed ID: 10792764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Secreted Larval Acidic Proteins (SLAPs) of Onchocerca spp. are encoded by orthologues of the alt gene family of Brugia malayi and have host protective potential.
    Wu Y; Egerton G; Pappin DJ; Harrison RA; Wilkinson MC; Underwood A; Bianco AE
    Mol Biochem Parasitol; 2004 Apr; 134(2):213-24. PubMed ID: 15003841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA vaccine encoding the moonlighting protein Onchocerca volvulus glyceraldehyde-3-phosphate dehydrogenase (Ov-GAPDH) leads to partial protection in a mouse model of human filariasis.
    Steisslinger V; Korten S; Brattig NW; Erttmann KD
    Vaccine; 2015 Oct; 33(43):5861-5867. PubMed ID: 26320419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential cytokine and antibody responses to adult and larval stages of Onchocerca volvulus consistent with the development of concomitant immunity.
    MacDonald AJ; Turaga PS; Harmon-Brown C; Tierney TJ; Bennett KE; McCarthy MC; Simonek SC; Enyong PA; Moukatte DW; Lustigman S
    Infect Immun; 2002 Jun; 70(6):2796-804. PubMed ID: 12010965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linear epitopes in Onchocerca volvulus vaccine candidate proteins and excretory-secretory proteins.
    Lagatie O; Verheyen A; Van Dorst B; Batsa Debrah L; Debrah A; Stuyver LJ
    Parasite Immunol; 2018 Nov; 40(11):e12587. PubMed ID: 30188578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired antibody responses and loss of reactivity to Onchocerca volvulus antigens by HIV-seropositive onchocerciasis patients.
    Tawill SA; Gallin M; Erttmann KD; Kipp W; Bamuhiiga J; Büttner DW
    Trans R Soc Trop Med Hyg; 1996; 90(1):85-9. PubMed ID: 8730320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-Administration of Adjuvanted Recombinant
    Luu L; Bah GS; Okah-Nnane NH; Hartley CS; Glover AF; Walsh TR; Lian LY; Zhan B; Bottazzi ME; Abraham D; Petrovsky N; Bayang N; Tangwa B; Ayiseh RB; Mbah GE; Ekale DD; Tanya VN; Lustigman S; Makepeace BL; Graham-Brown J
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection.
    Soboslay PT; Geiger SM; Weiss N; Banla M; Lüder CG; Dreweck CM; Batchassi E; Boatin BA; Stadler A; Schulz-Key H
    Immunology; 1997 Apr; 90(4):592-9. PubMed ID: 9176114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure.
    Makepeace BL; Jensen SA; Laney SJ; Nfon CK; Njongmeta LM; Tanya VN; Williams SA; Bianco AE; Trees AJ
    PLoS Negl Trop Dis; 2009 Nov; 3(11):e544. PubMed ID: 19901988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a recombinant vaccine against human onchocerciasis.
    Abraham D; Graham-Brown J; Carter D; Gray SA; Hess JA; Makepeace BL; Lustigman S
    Expert Rev Vaccines; 2021 Nov; 20(11):1459-1470. PubMed ID: 34488533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and characterization of Ov-47, a dominant antigen of Onchocerca volvulus.
    Ghogomu SM; Souopgui J; Pelle R; Titanji VP
    Exp Parasitol; 2002 Mar; 100(3):143-9. PubMed ID: 12173398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.